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Abstract
Although clinically distinguishable, migraine and cluster headache share prominent features such as unilateral pain,
common pharmacological triggers such glyceryl trinitrate, histamine, calcitonin gene-related peptide (CGRP) and
response to triptans and neuromodulation. Recent data also suggest efficacy of anti CGRP monoclonal antibodies in
both migraine and cluster headache. While exact mechanisms behind both disorders remain to be fully
understood, the trigeminovascular system represents one possible common pathophysiological pathway and
network of both disorders. Here, we review past and current literature shedding light on similarities and differences
in phenotype, heritability, pathophysiology, imaging findings and treatment options of migraine and cluster
headache. A continued focus on their shared pathophysiological pathways may be important in paving future
treatment avenues that could benefit both migraine and cluster headache patients.
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Background
In the field of cephalalgias, migraine has a prominent role
(35,311 publications retrieved for search terms “migraine”
in PubMed, accessed on August 15, 2018), with the recent
breakthrough in therapeutics, represented by the success-
ful clinical development of calcitonin gene-related peptide
(CGRP) antibodies [1]. However, in the last 40 years, the
number of papers published yearly for cluster headache
(CH) has been constantly increasing (3845 publications
retrieved for search terms “cluster headache” in PubMed,
accessed on August 15, 2018), and new evidence is accu-
mulating about epidemiology, including gender issues,
pathophysiology and imaging. Differences and similarities
between the two cephalalgias are presented here with a
comparative approach. The clinical continuum that unex-
pectedly but not infrequently characterizes migraine and
CH patients increases the value of such a comparison
between the two diseases.
Epidemiology and genetics in migraine and
cluster headache
Migraine is a highly prevalent disease, affecting at least 12%
of the general population [2], with a lifetime prevalence up
to 25% among women [3]. CH is a primary headache disease
with an estimated prevalence at 0.5–1.0/1000 of the general
population [4]. Both migraine and CH can be present from
childhood and their prevalence increases until nearly 40 years
of age, after which it gradually decreases [3, 5]. Twin studies
demonstrate a heritability around 42% for migraine [6]. Five
concordant monozygotic twin pairs with CH have been re-
ported [7], indicating the importance of genetic factors in
both disorders. The risk of first-degree relatives of patients
with CH to develop CH is between five and fifteen times
greater than that of the general population [7]. However, CH
does not exhibit a clearly recognizable inheritance pattern.
The genetic background of CH has been an unexplored field
for years; genetic studies have been performed only recently,
in small numbers of patients or as case reports. To date, tar-
geted genes have been investigated, including the calcium
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voltage-gated channel subunit alpha1 A (CACNA1A) [8],
three nitric oxide synthase (NOS) genes [9], the period circa-
dian regulator 3 (PER3) [10] and the hypocretin receptor 2
(HCRTR2) [11], and none showed evidence of involvement
in CH. In some families, the mode of inheritance is likely to
be autosomal dominant with incomplete penetrance; in
other families, it is more likely to be multifactorial or auto-
somal recessive [12, 13] (see Table 1).
In migraine, first-degree relatives of patients have a 3-fold
increase in migraine, compared to the general population
[14]. The risk increases in migraine with typical aura, sup-
porting the idea that distinct genetic factors may regulate
the inheritance of specific forms of migraine [15]. Rare
monogenic migraine subtypes can be caused by precise
genetic mutations, as in the case of familial hemiplegic mi-
graine; a rare genetic disorder with dominant autosomal
transmission due to mutations of three main genes (CAC-
NA1A, ATP1A2 and the sodium channel 1 A SCN1A)
[16]. These genes are not involved in common migraine
[17] or in CH [8], in which numerous genes and environ-
mental factors contribute to susceptibility in a manner still
unclear. Several studies have failed to identify any
association between genetic variants and common forms of
migraine indicating that autosomal-dominant inheritance is
unlikely, unless the penetrance of the gene is very low.
Migraine is currently considered a polygenic disorder:
multiple predisposing genes contribute, each with a small
effect size, to the underlying risk [16]. New gene alterations
have recently been related to CH [18–20], and a large
meta-analysis has mapped 38 distinct genomic loci
expressed in vascular and smooth muscle tissues, associated
with migraine [21]. These results should be furthered in
larger populations. Although both diseases are character-
ized by family aggregation, most noticeable in adulthood,
CH is a rare disease, with a stronger genetic influence. Ac-
cordingly, the mode of inheritance is likely to be different
between migraine and CH, and whether some genetic traits
are shared between the two disorders is unknown.
Pathophysiology
In the pathophysiology of migraine and CH, both the per-
ipheral nervous system and central nervous system are
involved. Three key structures interact and subsequently
involve cortical areas as well: the trigeminovascular sys-
tem, parasympathetic nerve fibers (trigeminal autonomic
reflex) and the hypothalamus [22].
Trigeminovascular system and trigemino-cervical reflex
In migraine and CH, pain is likely due to activation of the
trigeminovascular system [22]. Nociceptive nerve fibers
originate from the trigeminal ganglion (TG) and reach
intracranial structures such as the dural, arachnoid and
pial blood vessels, cerebral arteries and extracranial struc-
tures [22–25]. From TG the nociceptive signals project to
neurons in the trigeminal cervical complex (TCC), includ-
ing the trigeminal nucleus caudalis (TNC), and the dorsal
horn of the upper cervical spinal cord (C1-C2) [24–27].
These projections from the TCC terminate on neurons of
the trigeminal brainstem nuclear complex [28] and trans-
mit all somatosensory information via further projections:
to thalamic neurons (via a trigemino-thalamic tract), to
hypothalamic nuclei (via a trigemino-hypothalamic tract),
to basal ganglia nuclei and to brainstem nuclei including
the locus coeruleus (LC) and periaqueductal gray (PAG)
[25, 26, 28–30]. Subsequently, these structures reach sev-
eral cortical areas involved in processing aspects of the
nociceptive signals [26, 30].
Neuroimaging and neurophysiological investigations
Various neuroimaging studies implicate the brainstem in
the pathophysiology of migraine and CH. In migraine, ab-
normalities are seen in both ascending and descending
nociceptive pathways during ictal and inter-ictal phases
[31]. Positron emission tomography (PET) imaging studies
showed increased dorsal pons activation in migraine pa-
tients during the ictal phase [32]. Functional magnetic res-
onance imaging (fMRI) studies reported increased
functional connectivity between the cortical and subcor-
tical regions involved in nociceptive processing and the
PAG [33, 34], having connections coming from the thal-
amus, hypothalamus, and autonomic nervous system [31].
A dysfunction of pain control systems in both headaches
and a role of the brainstem in their pathogenesis is also
supported by neurophysiological studies. In migraine, loss
Table 1 Epidemiological and genetic similarities and differences in migraine and cluster headache
Migraine Cluster headache
Epidemiology and
genetics
Predominant in adulthood [3, 5] Predominant in adulthood [3, 5] Similarities
Familial aggregation [6] Familial aggregation [7]
12-15% of the general population [2] 0.5-1 ‰ of the general population [4] Differences
The first-degree relatives of patients have a 3-fold
increase of migraine headache, compared with the
general population [14]
The risk of first-degree relatives of patients to develop CH is
between five and fifteen times greater than that of the
general population [7]
Supposed mode of
inheritance
Polygenic disorder and rare monogenic variants [15] Autosomal dominant with incomplete penetrance,
multifactorial or autosomal recessive [12, 13]
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of habituation, lower cortical pre-activation and abnormal
sensitization was seen [35]. In CH, altered pain perception
and decreased pain thresholds was found [36].
In migraine some studies reported that the blink reflex
(which reflects excitability of interneurons in the brain-
stem) is delayed and reduced in amplitude [37, 38].
However, other studies did not confirm these conclu-
sions [39, 40]. In cluster headache patients, during active
phase, and on the headache side, a pronounced lack of
habituation of the brainstem and a general sensitization
of pain processing is seen [41]. These results point to-
wards dysfunctional connections between the brainstem
and trigeminovascular system, again supporting the tri-
geminovascular hypothesis [38].
In summary, electrophysiological studies show that the mi-
graine brain presents some interrelated functional character-
istics: 1. lack of habituation of evoked responses to repeated
stimuli; 2. cortical dysexcitability. The lack of habituation
was reported by examining visual evoked potentials (VEP)
[41–50] by using magneto-electroencephalography [51, 52],
with somatosensory [45, 46] and auditory [53, 54] evoked
cortical potentials pain (laser, LEP) [55] and event-related
(contingent negative variation) responses [56, 57] in migraine
between attacks [58]. Regarding cortical dysexcitability, con-
flicting results were presented in various trials, suggesting
cortical hypoexcitability [59, 60] as well as hyperexcitability
[61, 62]. Recent works suggest that abnormal rhythmic
activity between thalamus and cortex induce a low level of
cortical preactivation. This might explain the abnormal func-
tional characteristics in migraine mentioned above.
Abnormal processing could be due to hypoactivity of some
pathways (such as the serotonergic pathway), causing height-
ened response to repeated stimuli, thus resulting in an exces-
sive energy demand [63]. Changes in energy demand may
disrupt cerebral metabolic homeostasis and thus activate the
major alarm signalling system of the brain, the trigeminovas-
cular system, ultimately resulting in a migraine attack [63].
Trigeminal autonomic reflex and cranial parasympathetic
symptoms
Somatosensory pathways are connected to autonomic path-
ways through reflex connections from the TNC to the su-
perior salivatory nucleus (SuS). The SuS contains neurons
that are part of the cranial parasympathetic autonomic
vasodilator pathway [28, 64, 65]. These neurons project to
the cranial vasculature, including dura mater, to the nasal
and oral mucosa and lacrimal glands mainly through the
sphenopalatine ganglion (SPG) [28]. Activation of the cra-
nial SuS-parasympathetic pathway is believed to directly
contribute to cranial autonomic symptoms found in cluster
headache and up to 50% in migraine patients [29, 66].
Indeed, activation of this pathway induces a dilation of
intracranial vessels and a cascade of events that results in
plasma protein extravasation, neuropeptide release from
dural vascular terminals of post-SPG neurons [28], local
dural release of inflammatory mediators with perivascular
alteration and activation and sensitization of the trigemino-
vascular system [23, 27]. The SuS also has a bidirectional
connection with the hypothalamus (including the lateral
[65, 67], paraventricular, dorsomedial and pre-optic
hypothalamic nuclei [65, 68]), as well as with the limbic
and cortical areas [65].
Hypothalamus
The hypothalamus is involved in numerous physiological
functions including controlling circadian rhythm [22, 69].
Furthermore, it has several connections involved in pain
modulation in migraine as well as in cluster headache [36].
The hypothalamus also partakes in autonomic and endo-
crine regulation [23]. Preclinical data show that specific
hypothalamic nuclei, such as the paraventricular and lateral
hypothalamus, reach the TNC and SuS neurons through
descending projections [22, 65, 67, 68, 70, 71], thus influen-
cing and triggering somatosensory and autonomic neuro-
vascular mechanisms [23]. The premonitory symptoms of
headaches are considered the clinical side of an underlying
hypothalamic dysregulation. Many neuro-endocrinological
data support the hypothesis of hypothalamic–pituitary–ad-
renal axis failure in these primary headache disorders [72].
Neuroimaging and neurophysiological investigations
fMRI studies report a role of the hypothalamus in pain
modulation during the pre-ictal phase of attacks in mi-
graine patients. Particularly, it is hypothesized that the
anterior part of the hypothalamus may be involved in
migraine chronification, whereas the posterior part may
play a role in the acute pain phase [73].
In CH, activation in the hypothalamic grey matter ipsi-
lateral to the side of a headache during attacks is seen with
PET [74] and fMRI [75]. Also, altered functional connect-
ivity of the hypothalamus and anterior thalamus were de-
scribed. A voxel-based morphometry (VBM) study [64]
revealed concomitant grey matter volume increase of this
hypothalamic region, but other VBM studies did not sub-
stantiate these results [76–79]. Interestingly, a recent work
[80] hypothesized that the anterior hypothalamus might
contribute to the circadian rhythm of CH attacks [22],
whereas the posterior part might generate the restlessness
experienced by CH patients during the attack [81].
Alterations of resting state activity [82], were found in the
attention network ipsilateral to the pain and in the contralat-
eral cerebellar network. This result coincides with previous
repetitive transcranial magnetic stimulation (rTMS) studies
showing increased cortical excitability ipsilateral to the pain
in CH [82], similar to that in a migraine [83]. Resting state
studies showed altered activity of the medial frontal cortex
which is part of various resting state networks important in
pain perception [75, 84]. This disorganized connectivity
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could be a consequence of white matter microstructural al-
teration described in CH [85].
Lastly, cognitive processing studies employing
event-related potentials are useful in elucidating cortical acti-
vation time courses during cognitive processing [86, 87]. The
hypothalamic dysfunction might also explain the habituation
deficit of the brainstem and the general sensitization of pain
processing detected in patients with CH [88]. Neurophysio-
logical studies of sensory evoked potentials show various ab-
normalities but not as homogenously as displayed in
migraine [89–91]. The intensity dependence of auditory
evoked potentials is also increased in CH patients, during
and outside active phase, possibly suggesting decreased sero-
toninergic activity in the hypothalamic pathways [92].
Other brain structures
In addition to the above-mentioned studies involving brain-
stem and hypothalamus, patients with primary headaches ex-
perience dynamic structural [93] and functional [75] changes
in cortical-subcortical areas involved in nociception.
In migraine, fMRI and resting-state fMRI studies show
marked abnormalities both ictally and interictally in areas
involved in nociceptive processing and networks involved
in mediating cognitive, attentional, somatosensory and
emotional components of pain [33, 52, 94–97], respect-
ively. These networks may influence multisensory integra-
tion and pain experience in migraine patients. Structural
MRI studies also show a decrease in grey matter in various
regions of the brain such as frontal, parietal and temporal
cortex (Table 2). However, neuroimaging data on the asso-
ciation of white matter hyperintensities and migraine has
been conflicting. Some studies show a higher occurrence
of subcortical, deep, and cerebellar ischemic hyperintensi-
ties in migraineurs [98], whereas other studies fail to con-
firm such findings [99].
In CH, a decrease of the grey matter in several regions
was shown using structural MRI [78]. Structural alterations
in the striatum [93, 100] and atrophy of the thalamus and
the caudate nucleus has also been reported. Importantly, in
addition to a decrease also an increase in the right cuneus
was observed [78]. Recent resting-state fMRI studies found
Table 2 Structural and Functional abnormalities in migraine and cluster headache
Migraine Cluster headache
Structural
MRI (VBM/
DTI)
Decreased Grey Matter in:
frontal lobes, prefrontal cortex, left medial prefrontal (MPFC), brainstem
cortex, cerebellum, temporal lobes Right Superior Temporal; bilateral
insula; cingulated cortex; orbitofrontal cortex right occipital lobe right
posterior parietal cortex [226–230]
Reduced Fractional Anisotropy values:
superior frontal lobe; medial frontal lobe; Right Inferior Frontal [227, 230]
Thickening of the cortical mantle in the Somatosensory cortex [231]
Decrease Grey Matter in:
right thalamus, bilateral posterior, Hypothalamus, right
posterior cingulate cortex, left inferior parietal lobe, head
of the right caudate nucleus, bilateral middle frontal gyrus,
right-middle temporal gyrus, right precentral gyrus,
left insula [64, 78, 79]
Increased Grey matter:
right cuneus [78]
Grey matter volume changes:
Temporal lobe, hippocampus, insular cortex, cerebellum [77].
Changes in Fractional Anisotropy:
Brainstem, thalamus, internal capsule, superior and inferior
temporal region, frontal lobe, occipital lobe and cerebellum [101]
Cortical thinning was found in the contralateral angular
and precentral gyrus contralateral to the headache side [232]
fMRI Enhanced activation in:
perigenual part of anterior cingulate cortex [233] red nucleus, substantia
nigra [234], dorsolateral pons [24, 235], cerebellum, insula, cingulate,
prefrontal cortices, anterior temporal pole, hippocampus [32]
Decreased activation in: somatosensory cortex [233]
Enhanced activation in:
Posterior hypothalamus, anterior and posterior cingulate
cortex, thalamus, basal ganglia, cerebellar hemispheres,
prefrontal, insular and temporal cortices [64, 74, 95]
Structural
MRI (VBM/
DTI)
Stronger functional connectivity:
• periaqueductal grey to the ventrolateral prefrontal cortex,
supramarginal gyrus, anterior insula, precentral gyrus, postcentral
gyrus, and thalamus [33]
• anterior cingulate cortex to middle temporal, orbitofrontal cortex, and
dorsolateral prefrontal cortex [229]
• caudate nucleus to the parahippocampal gyrus, amygdala, insular cortex,
and putamen; nucleus accumbens to the parahippocampal, anterior
cingulate cortex, orbitofrontal cortex [236]
• Medial prefrontal cortex to the posterior cingulate cortex (coppola 2017)
• Medial prefrontal cortex and left to the right inferior parietal lobules
and bilateral insula [237]
Atypical Functional connectivity of:
• salience network, default mode network, central-executive network,
somatomotor network, and frontoparietal attention network [34]
• left rostral anterior cingulated cortex, bilateral prefrontal cortex
and right thalamus [97]
Stronger functional connectivity of:
• hypothalamus to parts of the frontal, parietal and temporal
cortex during headache free intervals; to the Anterior
Cingulate Cortex and Posterior Cingulate Cortex during the
acute spontaneous CH [87]
• attention network ipsilateral to a headache paine and in
the contralateral cerebellar network [75]
Atypical Functional connectivity of:
• the hypothalamus both ipsilateral and contralateral to the
CH side and the salience network [238]
Decreased functional connectivity of:
• the hypothalamus with the medial frontal gyrus, precuneus
and cerebellar areas [97]
VBM voxel based morphometry, DTI Diffusion Tensor Imaging
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abnormal functional connectivity in the sensorimotor and
primary visual networks during the pain-free period, as well
as between the hypothalamus and pain network areas in ac-
tive phase [84, 87, 95] (Table 2). Diffusion-tensor imaging
studies investigating white matter microstructural changes
offer contradictory findings [36, 78, 101]. Some report the
absence of white matter abnormalities [78]. Others report
widespread white matter microstructural changes, particu-
larly in the pain networks such as the frontal lobe, parietal
lobe, temporal lobe and thalamus [36, 85].
Clinical picture
Phenotypes
Migraine and CH are diagnosed according to the Inter-
national Classification of Headache Disorders (ICHD-3),
which are evidence-based primarily on patient popula-
tions [102]. Although the clinical presentation of mi-
graine and CH is usually different, these primary
headaches often share some similarities in the headache
phenotype, such as unilateral and severe pain and some
associated symptoms including aura [103, 104] (Table 3).
Moreover, coexistence of these two primary headaches
simultaneously has been reported [105].
CH attacks are usually associated with multiple prominent
ipsilateral cranial autonomic symptom, such as conjunctival
injection, lacrimation, rhinorrhea, forehead sweating, miosis
and/or ptosis [22, 106]. These symptoms have also been de-
scribed in migraineurs, but patients usually report only one
symptom (forehead sweating the most frequent) and in con-
trast to CH, they are less frequent, bilateral and mild [66].
Interestingly, different cohorts have revealed that CH
patients without comorbid migraine frequently experience
accompanying ‘migrainous associated symptoms’, such as
photophobia, phonophobia, nausea or vomiting [104, 107].
Furthermore, CH attacks are associated with specific chro-
nobiological features, mainly circadian (most frequently
nocturnal) and circannual (most frequently spring or au-
tumn) rhythms [22]. In contrast, migraine attacks are most
frequently reported to occur during the day and no clear
seasonal rhythm has been stablished yet [108].
When migraine attacks occur on 15 or more days/month
for more than three months it is considered chronic [102].
Each year 2.5–3% of patients with episodic migraine trans-
form to chronic migraine (CM), fortunately these patients
frequently revert back to episodic migraine [109, 110].
CH attacks occurring for one year or longer without re-
mission or with remission periods lasting less than three
months (10–15%) are classify as chronic [102]. CCH may
be unremitting from onset (de novo), or evolve from the
episodic type and in some patients a change from chronic
to episodic may occur [111]. Furthermore, a recent consen-
sus from the European Headache Federation defined refrac-
tory CCH as a situation that fulfills ICHD-3 for CCH with
at least three severe attacks per week despite at least three
consecutive trials of adequate preventive treatments [112].
Triggers
Migraine and CH patients report a remarkable number
of common triggers – both naturally occurring events
such as stress, sleep, alcohol intake and weather changes
[106, 107, 113], but also pharmacological triggers [22,
114]. It has been suggested that these triggers are com-
mon trigeminal system activators [105, 109].
Identification and avoidance of attack triggers plays an
important role in management of patients with migraine
and CH. Attack triggers may also provide clues to their
underlying pathophysiology [115]. While naturally oc-
curring attack triggers are useful in management of
Table 3 Clinical similarities and differences amongst cluster headache, migraine without aura and migraine with aura
Headache phenotype Cluster Headache Migraine without aura Migraine with aura
Location Strictly unilateral Usually unilateral Similarities
Intensity Severe/very severe Moderate/severe
Associated symptoms Nausea, photophobia and phonophobia
Aura (≈20%) [103] - Aura
Quality Excruciating, stabbing Deep, pulsating Differences
Duration 15-180 minutes 4-72 hours
Radiation Orbital, supraorbital and/or temporal Frontotemporal
Circadian/circannual rhythms Nocturnal [22]
Spring/autumn
Early morning [108]-
Frequency Once every other day to eight times a day Once every other day
Most common triggers Alcohol [5] Stress, cycling female hormones [239], [113] (but also
alcohol)
Aggravators - Routine physical activity
Cranial autonomic symptoms Ipsilateral, prominent Bilateral, mild [66]
Disability during headache Restlessness or agitation Severe impairment or require bed rest
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individual patients they may be of limited use in experi-
mental provocation studies. Thus, in a study of
self-reported triggers of migraine with aura only 17% of
patients developed an attack following exposure to their
natural attack trigger [116]. For a comprehensive review
on specific natural attack triggers of primary headaches
see Pellegrino et al. 2017 [115].
The earliest pharmacological provocation studies in
migraine and CH patients explored histamine [117–119]
and found that histamine infusion, which causes en-
dogenous nitric oxide (NO) formation, induces attacks
in both migraine and CH. In a double-blind, randomized
pretreatment study in 20 migraine patients without aura
(MwoA) [117], a 20 min intravenous histamine infusion
was pretreated with mepyramine (0.5 μg/kg/min for
10 min) or placebo infusion (n = 10, each). In the pla-
cebo pretreated group 7 of 10 MwoA patients reported
migraine-like attack following histamine infusion com-
pared to 0 of 10 in the mepyramine group. In the pla-
cebo pretreated group the average time to peak
headache was 5 h. In CH, nine patients received sub-
cutaneous injection of histamine (0.01 mg/kg body
weight) [120]. All nine CH patients developed CH-like
attacks after a median time of 45 min. The study was
neither blinded nor placebo controlled.
Glyceryl trinitrate (GTN), a prodrug of NO, was given
intravenously (0.5 μg/kg/min for 20 min) in a double-blind,
placebo controlled, cross over study on 12 MO patients
[121]. At a median time of 5.5 h after GTN infusion 8 of 10
patients fulfilled criteria for a migraine attack compared to
only one after placebo. In CH, several non-placebo con-
trolled provocation studies found that GTN induces CH in
episodic active phase in 33–100% of patients [122–125]
and in CCH in 20–78% of patients [125, 126]. In remission
phase episodic CH patients GTN induced no attacks [122–
124]. Mean time to onset of attacks was 12–72 min after
infusion start [120, 122, 124]. NO, among other things, in-
creases intracellular cyclic guanosine monophosphate
(cGMP) [127]. Sildenafil, a phosphodiesterase 5 inhibitor,
which also increases intracellular cGMP, also induced mi-
graine attacks in 10 of 12 MO patients compared to 2 of 12
after placebo [128]. In CH, cases of sildenafil (prescribed
for erectile dysfunction) triggering CH attacks in active
phase [129, 130] and even triggering an active phase itself
[131] have been reported. In a randomized, double-blind,
placebo controlled cross-over study in 12 MwoA patients,
vasoactive signaling molecule CGRP was infused intraven-
ously (2.0 μg/min for 20 min) [132]. In the paper, authors
stated that three of nine MO patients developed delayed
migraine attacks as strictly defined by criteria from the
International Headache Society on CGRP compared to zero
of nine on placebo. When revisiting these results and apply-
ing newer, modified criteria for pharmacologically induced
migraine-like attacks, CGRP induced delayed migraine-like
attacks in six of nine MO patients compared to one in nine
after placebo [133]. In a recent study, 32 CH patients (9
episodic active phase, 9 episodic remission phase, and 14
chronic) received intravenous infusion of CGRP (1.5 μg/
min for 20 min) or placebo in a randomized, double-blind,
placebo controlled cross-over study [134]. CGRP induced
cluster-like attacks in 89% of episodic active phase patients
compared to 11% after placebo, and in 50% of chronic pa-
tients compared to 0% after placebo. In episodic remission
phase CH patients neither CGRP nor placebo induced any
attacks. Median time to onset of attacks was 20 min in
CCH and 30 min in episodic active phase CH. This was the
first placebo controlled provocation study in CH. Authors
conclude that these findings point to the possibility of effi-
cacy of CGRP antagonism, already known to prevent and
abort migraine [135–138], in CH as well. Such antibodies
against CGRP are currently under investigation in CH [22].
Recently the efficacy in reduction of weekly attacks in epi-
sodic but not CCH was announced [139].
Thus, although migraine and CH have several pharma-
cological triggers in common, the time to onset of attacks
seems to vary predictably between the two diseases with
CH generally being triggered faster than the average in-
duced migraine attack [117, 120, 132, 140, 141]. In mi-
graine, delayed attacks are thought to arise from the
pharmacological trigger playing a role relatively early in
spontaneous migraine attack initiation [114]. Thus, the
short time to attack in CH might reflect a shorter cascade
of events in CH attack initiation relative to migraine.
Migraine and CH are linked pathophysiologically by
common neuronal structures, however, they are (usually)
influenced differently by lifestyle, environmental, hormo-
nal and genetic factors [107]. This shared pathophysiology
is supported by common environmental and pharmaco-
logical attack triggers and similar efficacy with some treat-
ments (see next section). Unfortunately, research about
the pathophysiological interactions between diseases is
scarce and these questions remain to be elucidated.
Gender aspects
Migraine and CH show distinct and inverse gender-related
characteristics. Migraine is two to three times more com-
mon in women than in men, estimates varying from 13% to
17% for females and 7.6% to 10% for males [142]. On the
contrary, CH is a male-dominated disorder with the ratio
of men to women estimated to range from 3:1 to 7:1 [143].
Puberty is a turning point for the predominance of gender
in both primary headaches, which in childhood show a
similar distribution by gender [144, 145]. According to the
onset of the disease, gender differences are more evident in
the third decade of life for both migraine and CH, and
women with CH show a further peak of incidence between
the ages of fifty and sixty years [143]. In older people, the
gender-related aspects vanish in both disorders.
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Women experience migraine or CH differently than
men. Women report more severe and longer attacks
[146]. Moreover, women with migraine are more likely to
report nausea, vomiting, photophobia, phonophobia and
aura associated with headache [147]. Men and women
with CH have similar clinical phenotypes [148], with no
apparent differences in pain intensity, quality and location.
Women with CH report more nausea and vomiting than
men, but it is unclear whether this is caused by a generally
higher proportion of concomitant migraine [149]. Add-
itionally, women with CH appear to respond more poorly
to some abortive and preventative treatments [150]. The
reasons for the opposite gender characteristics in migraine
and CH are not fully understood. The underlying causes
are likely to be multifactorial, involving both biological
and psychosocial factors. Among biological factors, previ-
ous studies have focused on fluctuations in sex hormones
and the exploration of genetic factors, without obtaining a
definitive response [151].
Treatment
Migraine and CH therapy includes the acute therapy to
abort the single attack, and preventive therapy to reduce
attack frequency, duration and severity and the use of
acute headache medications.
Acute therapy
As in migraine, CH attacks respond well to acute therapy
with triptans [152–154]. Nevertheless, differently from mi-
graine, the oral route of administration is not usually rec-
ommended in CH, because of the delayed effect compared
to subcutaneous or intranasal administration. On the other
hand, acetaminophen and non-steroidal anti-inflammatory
drugs are only used in the acute therapy of migraine and
not in CH [155]. Shared pathophysiological mechanisms as
reviewed in previous sections could explain the efficacy of
triptans in both diseases.
Another acute approach for the treatment of CH attacks
is inhalation of 100% oxygen through a face mask (with a
flow of 12–15 l/min). Interestingly, a recent randomized
placebo-controlled clinical trial on 22 patients reported that
high-flow oxygen was significantly more effective than air
in the acute treatment of migraine attacks [156], and it has
been suggested that this treatment could have greater re-
sponses in migraine patients with cranial autonomic symp-
toms [157] or migraine-cluster and cluster-migraine
variants (these rare phenotypes are not included in the
ICHD-3). An inhibition of activated trigeminal nociceptive
afferents or the autonomic pathway could be one of the
mechanisms explaining its efficacy in both migraine and
CH [158].
Lastly, in patients affected by CH, when oxygen and
triptans are ineffective, intranasal lidocaine (sprayed in
the ipsilateral nostril) should be considered [125]. Clin-
ical trials provided conflicting data about its efficacy in
migraine [159–161].
Taken together, the previous suggests that, although
with different preferable route of administration (for
triptans) and response rate (for oxygen inhalation) mi-
graine and CH share responsiveness to some acute strat-
egies (see Table 4).
Preventive therapy
Different drug categories are effective in the prophylactic
treatment of patients affected by episodic or CCH, even
though, unlike in migraine, few randomized clinical trials
have been conducted [162]. Similarities and differences in
migraine and CH preventive therapies are summarized in
Table 5.
High-dose verapamil is the most frequently used in CH
preventive therapy [163]. Interestingly, few studies sug-
gested the efficacy of verapamil in migraine prophylaxis
[164, 165]. Lithium carbonate is mainly used as a prophy-
lactic drug in CCH to reduce the attack frequency in pa-
tients [166, 167]. To date, no randomized clinical trials
have studied the efficacy of lithium in migraine prophy-
laxis. Small open trials reported conflicting results in mi-
graine [168, 169]. A short term effective therapy for CH is
represented by prednisone [77, 170] which can be used for
short-duration episodes or to induce a rapid remission
(usually within 3–10 days). Evidences about the use of ste-
roids in the preventive therapy of migraine do not allow
precise conclusions. Nevertheless a recent review showed
that steroids demonstrated a good efficacy in reducing the
recurrence of migraine in patients visiting the emergency
department for acute attacks [171]. Blockade of the
greater occipital nerve (GON) ipsilateral to the pain, with
injection of corticosteroids and local anesthetic is effective
in CH [172] and was also shown to be effective in treat-
ment of CM [173].
In migraine, the efficacy of sodium valproate and
topiramate has been documented in RCTs [174, 175]. In
Table 4 Efficacy of acute therapies in migraine and cluster headache
Migraine Cluster headache
NSAIDs Effective [155] Not effective
Triptans Oral route of administration Subcutaneous sumatriptan/ intranasal sumatriptan or zolmitriptan [153, 154] effective
Inhalatory oxygen Effective in about 46% of patients [156] Effective: about two-third of patients [240]
Intranasal lidocaine Conflicting data [159, 160] Effective [125, 241]
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CH, even though open uncontrolled studies indicated a
good efficacy, RCTs did not show any clinical efficacy of
sodium valproate and topiramate [176–180].
Open trials showed clinical efficacy of local injection of
onabotulinumtoxin A into the sphenopalatine ganglion
(SPG) both in CH [181] and in refractory CM therapy
[181]. The Phase III REsearch Evaluating Migraine Prophy-
laxis Therapy 1 and 2 (PREEMPT 1 and 2) have shown the
efficacy of Onabotulinumtoxin A in reduction of headache
days in CM, using a specific injection protocol [182, 183].
The PREEMPT study protocol was also used in a 28 week,
open-label trial, with refractory CCH [184]. A more than
50% reduction in headache minutes was reached in 58.8%,
whereas 29.4% experienced a 30–50% of improvement.
Mean frequency of headache days dropped from 28 to
12 days at week 24 (p = .0001). Randomized controlled tri-
als are needed to confirm these encouraging results.
Randomized clinical trials have indicated that mela-
tonin may be effective for the preventive treatment of
CH, with a daily dose of 10 mg [185] and migraine, with
a dose of 3 mg [186].
Anti CGRP monoclonal antibodies (mAbs) are effect-
ive in migraine prophylaxis [135–138] and the anti
CGRP receptor mAbs erenumab is now approved by
Food and Drug Administration (FDA) [187]. Ongoing
trials (NCT02964338, NCT02797951, NCT02397473,
NCT02438826) are investigating the efficacy of anti
CGRP mAbs in CH. Recently, an Eli Lilly press release
announced that a phase 3 study (NCT02797951) showed
that galcanezumab reduced weekly attacks in episodic
but not CCH patients [188].
The efficacy of anti CGRP monoclonal antibodies and
greater occipital nerve (GON) blockade in both migraine
and CH indicates that the activation of the trigeminovas-
cular system (with consequent release of CGRP) and the
TCC is a key mechanism involved in the pathogenesis of
both migraine and CH. Furthermore, the good response
to oral corticosteroids as a transitional treatment may in-
dicate that they may reduce the neurogenic inflammation
induced by the activation of the trigeminovascular system
in both diseases. The efficacy of melatonin in the
prophylactic therapy for both migraine and CH points to-
wards a pathogenetic role for the hypothalamus and the cir-
cadian rhythm regulation system in both migraine and CH.
The pharmacological effect of verapamil is probably due to
the interactions with muscarinic, serotoninergic and dopa-
minergic receptors, the inhibition of presynaptic adrenergic
receptors (with a consequent increase in noradrenaline re-
lease) and the modulation of pain pathways. Its efficacy in
both migraine and CH could be due to the modulation of
brainstem circuitries, the rebalancing of autonomic system
and the restoration of the pain control system [189].
In conclusion, even though the first line strategies for mi-
graine and CH treatment seem to be quite different, most of
the drugs used for CH prophylaxis also demonstrated a cer-
tain degree of efficacy in migraine prophylaxis, showing that
migraine and CH, even with their clinical differences may
share some of their basic pathophysiological mechanisms.
Neuromodulation
Invasive neuromodulatory procedures comprise stimula-
tion of the central nervous system, hypothalamic deep
brain stimulation (hDBS) and of the peripheral nerves
(occipital nerve stimulation, ONS; SPG). Non-invasive
variants comprise vagus nerve stimulation (VNS), supra-
orbital nerve stimulation (SNS), rTMS and transcranial
direct current stimulation (tDCS).
The rationale for the use of hDBS is an increased blood
flow in the posterior hypothalamus during cluster [74]
and migraine attacks [190], which was interpreted as neur-
onal activation of that brain area. hDBS has been shown
to be highly effective in CH, with significant reduction of
attack frequency and with the ability to change disease
course [22, 191–193]. Although the treatment effects
seem clinically equal, the side effects of the more invasive
hDBS treatment are to be considered [194]. So far, there is
no evidence to support the use of hDBS in CM.
The basis for the use of ONS in headaches came from
animal studies showing the convergence of cervical, som-
atic and dural afferents on second order nociceptors in the
trigeminocervical complex [195, 196]. More or less all these
structures are involved in the pathophysiology of CM and
Table 5 Efficacy of preventive therapies in migraine and cluster headache
Migraine Cluster headache
Verapamil Effective [242] Effective in high-dose (360 up to 960 mg)
Litihum No large RCTs; ineffective in small trials; efficacy clues in “cyclic
migraine” [169]
Effective [166]
Steriods Reduced recurrence of attacks in patients coming to emergency
department [171]
Effective (usual dosage ≥40 mg)
Antiepileptic
drugs
Effective Efficacy clues in open uncontrolled studies, not
confirmed by RCTs.
GON blockade Effective in chronic migraine [173] Effective [172, 243]
Melatonin 3 mg per day are effective [186] 10 mg per day are effective [185]
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CH. For ONS, to date, 3 RCTs have been performed in CM
[197–199], and their outcome is overall disappointing. For
CH multiple isolated reports, case series, small cohort stud-
ies and observational studies suggested a 50% improvement
in headache frequency or intensity with ONS [200, 201].
The SPG is a large extracranial parasympathetic ganglion
located in the pterygopalatine fossa. Post-ganglionic para-
sympathetic fibers from the SPG innervate facial structures
such as the salivary and lacrimal glands, the nasopharyngeal
mucosa and the cerebral and meningeal blood vessels [202].
Mainly all these structures are involved in the pathophysi-
ology of CH and partially also in CM. SPG electrical stimu-
lation via an implantable device was proven for effective in a
multicentre randomised, double-blind and sham-controlled
trial in refractory CCH [203]. Full stimulation of the SPG
versus sham stimulation resulted in a significant pain relief
(67%) and a significant reduction in attack frequency (34%)
[203]. Only anecdotal cases have been reported for migraine
treatment with SPG, usually reserved for cases of refractory
migraine [204]. SPG has been targeted also with blockade
via bupivacaine, which showed, in CM, a sustained reduc-
tion of headache frequency in a double-blind, parallel-arm,
placebo-controlled, randomized pilot study [205].
VNS has been shown to be effective in both migraine
and CH. Indeed, in small open-label single-arm studies,
VNS had good migraine abortive effect, with 43 to 65% of
patients obtaining pain relief [206, 207]. The recent multi-
center, double-blind, randomized, sham-controlled
PRESTO trial confirmed VNS effective as abortive treat-
ment for migraine attacks, with consistent therapeutic
benefit compared to sham stimulation [208]. In the EVENT
trial, a double-blind sham-controlled study on migraine
prevention, though not reaching the primary outcome,
VNS led to a slight reduction in migraine frequency [209].
CH patients can also benefit from VNS. In an open-label,
prospective, randomized study, a significant reduction in
weekly attack frequency was observed among patients with
CCH receiving VNS plus standard of care compared to
standard of care alone [210, 211]. Moreover, VNS has been
shown to be cost-effective, providing economic benefits as
an adjunct treatment to standard of care in CCH [212].
rTMS has effect as prophylactic treatment in migraine
with aura. In a sham controlled randomized trial, single pulse
rTMS has been shown to increase in freedom from pain
after 2 h when applied early in the treatment of migraine
with aura, with substantial benefit for up to 48 h after treat-
ment [213] Although cortical excitability has been implicated
in CH [82], to date few data exist on rTMS in CH.
In migraine prevention, SNS has been extensively
studied and shown to provide a significant reduction of
migraine days compared to sham stimulation [214, 215].
On the contrary, SNS in CH has been poorly investi-
gated, and only isolated reports of possible positive neu-
romodulation among CH are available [216].
Overall, few data still exist on neuromodulation strategies
in headache disorders. Nevertheless, data from randomised
controlled trials seem to suggest safety and effectiveness in
both migraine and CH (see Table 6), supporting the con-
cept that these two diseases, despite their differences, might
share pathophysiological mechanisms. The common de-
nominator might be the hyperexcitability of brain network,
progressive changes in nociceptive thresholds and subse-
quent central sensitization. For CCH, SPG [217, 218] or
ONS [197, 219], given the risk/benefit profile of the inter-
vention, might be considered before hDBS. In migraine
VNS might be considered as an abortive effective treat-
ment, also able to spare symptomatic drugs. For patients
with CM the use of ONS, as well as the application of the
non-invasive VNS, tDCS, rTMS, cannot be recommended
so far, given the poor amount of controlled data.
Conclusions
Migraine and CH show remarkable similarities with
common triggers [22, 114], efficacy of triptans [220, 221],
Table 6 Efficacy of neuromodulation strategies in migraine and cluster headache
Intervention Migraine Cluster headache
Deep brain stimulation Isolated reports, no consistent data no RCT, available case series show significant
reduction in attack frequency but with
consistent side effects [22, 117–119]
Occipital nerve stimulation conflicting results from 3 RCT [197–199] no RCT, case series show 50% improvement in
frequency and intensity [200, 201]
Sphenopalatine ganglion stimulation no RCT, only anecdotal case reports
available
RCT shows SPG electrical stimulation is effective
in reducing intensity and frequency in refractory
chronic cluster headache [203]
Vagus nerve stimulation RCT shows effective as abortive treatment
[208], slight benefit on migraine frequency
in prophylaxis [209]
Conflicting results from RCT, more effective on
episodic CH than refractory chronic CH
Transcranial magnetic stimulation RCT shows benefit on migraine with
aura [213]
no RCT, no systematic reports available
Supraorbital nerve stimulation significant reduction in migraine
frequency [214, 215]
no RCT, only isolated reports available, possible
positive effect [216]
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anti CGRP monoclonal antibodies [135–138, 188] and
neuromodulation [222]. These observations raise an im-
portant question on possible shared pathophysiological
mechanisms. The central denominator in both diseases
may be the trigeminovascular pathway, alteration in hypo-
thalamic activity and functional changes in hypothalamic–
brainstem connectivity. A key signalling molecule, CGRP,
is involved in migraine and CH [223, 224]. The import-
ance of the pituitary adenylate-cyclase activating peptide
(PACAP) is well established in migraine [140] and an
ongoing phase 2 study is testing the efficacy of a PAC1 re-
ceptor antibody for migraine prevention [225]. Future
studies will show whether migraine and CH shares the
involvement of PACAP signalling in pathophysiology.
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